FDA v. Wages and White Lion Investments, LLC

Docket Number: 23-1038
Citation: 604/2
Term: October Term 2024
Argued: December 2, 2024
Decided: April 2, 2025
Lower Court: United States Court of Appeals for the Fifth Circuit
Author: Associate Justice Samuel A. Alito, Jr.
Concurring: Samuel A. Alito, Jr., Sonia Sotomayor

Read the official slip opinion (PDF)

AI-Generated Summary

Summary of FDA v. Wages and White Lion Investments, L.L.C., DBA Triton Distribution, et al.

1. Case Information:

Case Name: Food and Drug Administration v. Wages and White Lion Investments, L.L.C., DBA Triton Distribution, et al.
Docket Number: 23–1038
Dates: Argued December 2, 2024; Decided April 2, 2025
Lower Court: United States Court of Appeals for the Fifth Circuit

2. Facts of the Case:

Narrative of Events: This case centers on the Food and Drug Administration's (FDA) denial of premarket tobacco product applications submitted by respondents, Wages and White Lion Investments, L.L.C. (DBA Triton Distribution) and Vapetasia, L.L.C., for flavored e-liquids used in open-system electronic cigarettes (e-cigarettes). E-cigarettes, introduced as a potentially safer alternative to traditional cigarettes, have gained popularity, especially among youth, due to a variety of flavors like fruit, candy, and dessert. The Family Smoking Prevention and Tobacco Control Act of 2009 (TCA) granted the FDA authority to regulate tobacco products, including e-cigarettes, deemed as "new tobacco products" if not marketed before February 15, 2007. The FDA delayed enforcement to allow manufacturers time to submit applications, with a court-imposed deadline of September 9, 2020. The FDA denied over a million applications for flavored e-cigarette products in 2021, including respondents', citing insufficient evidence that marketing these products would be appropriate for public health protection.
Procedural History: Respondents submitted their applications by the 2020 deadline, but the FDA denied them in 2021. Respondents sought judicial review under the Administrative Procedure Act (APA) in the Fifth Circuit. Initially, a motions panel granted a stay, but a merits panel denied the petitions. The Fifth Circuit, sitting en banc, granted review, found the FDA acted arbitrarily and capriciously, and remanded the case to the FDA. The Supreme Court granted certiorari to resolve a circuit conflict and review the Fifth Circuit's decision.

3. Legal Issues Presented:

Questions Addressed: Did the FDA act arbitrarily and capriciously under the APA by denying respondents' premarket tobacco product applications for flavored e-cigarettes, particularly in light of alleged changes in application standards from predecisional guidance regarding scientific evidence, comparative efficacy, device type, and marketing plans?
Legal Basis: The case involves interpretation of the TCA (21 U.S.C. §387j) and the APA (5 U.S.C. §706(2)(A)), focusing on whether the FDA's actions adhered to administrative law principles, specifically the change-in-position doctrine.
Main Arguments: Respondents argued that the FDA changed its standards without adequate notice or consideration of reliance interests, particularly on scientific evidence requirements, cross-flavor comparisons, device type distinctions, and the importance of marketing plans. The FDA countered that its denials were consistent with guidance, or any deviations were justified or harmless error.

4. The Court's Decision (Main Opinion):

Author & Type: Justice Alito delivered the opinion for a unanimous Court.
Holding: The Supreme Court vacated the Fifth Circuit's conclusion that the FDA acted arbitrarily and capriciously regarding scientific evidence, comparative efficacy, and device type, finding the FDA's denials sufficiently consistent with predecisional guidance. On the issue of marketing plans, the Court clarified the harmless-error standard under the APA and remanded for the Fifth Circuit to apply the correct standard.
Legal Reasoning: The Court applied the change-in-position doctrine, which allows agencies to change policies if they provide reasoned explanations and consider reliance interests. For scientific evidence, the FDA's broad discretion under the TCA and noncommittal guidance meant no change occurred; denials were based on insufficient rigor in submitted evidence. For comparative efficacy, the FDA's requirement to compare flavored products to tobacco-flavored ones was a natural outgrowth of guidance emphasizing cross-product comparisons and youth appeal of flavors. Regarding device type, the FDA's focus on flavor over device type was consistent with guidance or justified by evolving evidence of youth demand shifts. On marketing plans, the FDA did not contest the change in position but argued harmless error; the Court rejected the Fifth Circuit's narrow reading of Calcutt v. FDIC and emphasized a broader harmless-error analysis under the APA, balancing with the remand rule from Chenery.
Disposition: The judgment of the Fifth Circuit was vacated and remanded for further proceedings consistent with the opinion, specifically to reassess the harmless-error issue regarding marketing plans.

5. Concurring Opinion(s):

Justice Sotomayor: Justice Sotomayor joined the Court's opinion but wrote separately to clarify that the FDA did not lack clarity or unwillingness in its guidance. Instead, she emphasized that the FDA provided reasonable flexibility on evidence forms while adhering to its statutory duty under the TCA to approve only products appropriate for public health protection, given the well-documented risks of flavored e-cigarettes to youth.

6. Dissenting Opinion(s):

None: There were no dissenting opinions in this case.

7. Potential Significance:

The ruling clarifies the application of the change-in-position doctrine in administrative law, affirming that agencies like the FDA have flexibility to evolve standards within statutory bounds without being deemed arbitrary, provided changes are reasonably consistent with prior guidance or justified. It also highlights the tension between the remand rule and harmless-error principles under the APA, potentially guiding future courts in balancing these doctrines in administrative reviews. The decision may influence how the FDA and other agencies issue guidance and handle premarket authorizations, particularly for products with significant public health implications like e-cigarettes, by underscoring the importance of consistency or reasoned justification in policy shifts.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Key terms: E-Cigarettes, FDA Regulation, Flavored Vapes